Logo do repositório
 
Publicação

Isradipine in the treatment of mild-to-moderate hypertension in geriatric patients

1994Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorRocha-Gonçalves, F.
dc.contributor.authorMoura, B.
dc.contributor.authorPereira Miguel, José
dc.contributor.authorCorrea-Nunes, A.
dc.contributor.authorMariano-Pego, G.
dc.date.accessioned2022-03-30T15:47:53Z
dc.date.available2022-03-30T15:47:53Z
dc.date.issued1994
dc.description© 1994 by the American Journal of Hypertension, Ltd.pt_PT
dc.description.abstractA number of studies have shown the benefit of hypertensive treatment even though the most common forms of the disease are mild-to-moderate in severity. Considering the overall aging of the world's population, it is of particular interest to study hypertension and its treatment in geriatric patients. A short-term study of isradipine was conducted to assess its effectiveness and tolerability in patients with mild-to-moderate hypertension. The study was carried out by general practitioners and involved 3343 patients, aged > or = 18 years, with diastolic blood pressures (DBPs) ranging from 95 to 114 mm Hg. A 4-week wash-out and placebo run-in phase was followed by a 12-week active treatment period with isradipine at 1.25 or 2.5 mg/day, depending on the blood pressure response. Posttreatment results in a subgroup of 1092 patients (444 men and 648 women), aged > or = 60 years, showed decreases in systolic blood pressure (SBP) from 173.1 to 149.2 mm Hg (mean decrease, 20.9 mm Hg) and, in DBP, from 102.0 to 85.0 mm Hg (mean decrease, 16.9 mm Hg). The majority (84.6%) of these patients showed DBP reductions of > 10 mm Hg, and 82.3% achieved normalization (DBP < 90 mm Hg) at the end of treatment. The mean dosage was 1.74 +/- 0.69 mg twice daily, and 37% of patients doubled their initial 1.25 mg twice daily dosages. There were no significant changes in either heart rate or major metabolic parameters. Adverse events were reported by 3.1% of the patients, and 90% of both patients and physicians expressed satisfaction with the therapy. There were no differences between men and women with regard to adverse events or efficacy, nor were the results in patients > or = 60 years different from those in younger patients. Thus, isradipine was effective and well tolerated in these geriatric patients.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAm J Hypertens. 1994 Jul;7(7 Pt 2):64S-66Spt_PT
dc.identifier.doi10.1093/ajh/7.7.64Spt_PT
dc.identifier.eissn1941-7225
dc.identifier.issn0895-7061
dc.identifier.urihttp://hdl.handle.net/10451/52106
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Presspt_PT
dc.relation.publisherversionhttps://academic.oup.com/ajhpt_PT
dc.subjectIsradipinept_PT
dc.subjectCalcium antagonistspt_PT
dc.subjectHypertensionpt_PT
dc.subjectElderlypt_PT
dc.subjectGeriatric medicinept_PT
dc.titleIsradipine in the treatment of mild-to-moderate hypertension in geriatric patientspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage66Spt_PT
oaire.citation.issue7_Pt_2pt_PT
oaire.citation.startPage64Spt_PT
oaire.citation.titleAmerican Journal of Hypertensionpt_PT
oaire.citation.volume7pt_PT
person.familyNamePereira Miguel
person.givenNameJosé
person.identifier.orcid0000-0003-4648-1658
person.identifier.scopus-author-id6602752350
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb374d24d-22fb-4bc6-a5ae-a54a76b3327a
relation.isAuthorOfPublication.latestForDiscoveryb374d24d-22fb-4bc6-a5ae-a54a76b3327a

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Isradipine_geriatrics.pdf
Tamanho:
426.89 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

FM-IMPSP-Artigos em Revistas Internacionais